Axsome Therapeutics (AXSM) Total Current Liabilities (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Total Current Liabilities data on file, last reported at $439.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 80.07% year-over-year to $439.2 million; the trailing twelve-month figure through Mar 2026 stood at $439.2 million (up 80.07% YoY), and the FY2025 full-year result was $378.8 million, up 64.64% from the prior year.
• Total Current Liabilities grew to $439.2 million in Q1 2026, from $378.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $439.2 million in Q1 2026 to a low of $24.5 million in Q1 2022.
• A 5-year average of $189.1 million and a median of $144.0 million in 2024 frame the typical range for Total Current Liabilities.
• Peak annual rise in Total Current Liabilities reached 318.64% in 2022, while the deepest fall reached 13.22% in 2022.
• Tracing AXSM's Total Current Liabilities over 5 years: stood at $96.6 million in 2022, then soared by 43.8% to $138.9 million in 2023, then soared by 65.72% to $230.1 million in 2024, then jumped by 64.64% to $378.8 million in 2025, then rose by 15.94% to $439.2 million in 2026.
• Business Quant data shows AXSM's Total Current Liabilities at $439.2 million in Q1 2026, $378.8 million in Q4 2025, and $360.3 million in Q3 2025.